ArticlePakistan journal of medical sciences2025
Comparative study of Exosome Ovarian Cancer auxiliary diagnostic kit (Chemiluminescence) and Serum Tumor Marker CA125 in the diagnosis of Ovarian Epithelial Cell Carcinoma.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the diagnostic performance of an exosomal ovarian cancer assay (chemiluminescence) with serum CA125 for epithelial ovarian cancer (EOC), focusing on sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Methodology: This retrospective study included 200 patients from the Department of Obstetrics and Gynecology, Hospital of 82nd Group Army PLA (June 2023 to December 2024). Participants were divided into a control group (n = 150, including healthy individuals, patients with pelvic inflammatory disease, and other tumors) and an EOC group (n = 50, confirmed by pathology). Serum samples were analyzed using the exosomal kit and CA125. Agreement metrics (PPA, NPA, OPA) with 95% CIs and Kappa consistency were calculated. Results: There were significant differences in age distribution and menopausal status between the two groups ( Conclusion: The exosomal ovarian cancer diagnostic kit exhibits superior sensitivity and specificity compared to CA125, suggesting strong potential as a complementary tool for early EOC detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.